Business & MarketsBreakingUpdated 1 hr ago

Eli Lilly reports third-quarter earnings and raises its outlook

Coverage spectrum

Covered by 3 outlets, all center.

3 articles in total. The spectrum counts each outlet once and leaves opinion out. How we measure bias

Image via CNBCHow images are chosen Report this image

CNBC, MarketWatch and the Financial Times report on Eli Lilly's third-quarter earnings. CNBC, previewing the release, says analysts expected growth to be fuelled by the obesity drug Zepbound and the diabetes drug Mounjaro, and that investors were watching early sales of Foundayo, the company's obesity pill launched in April. MarketWatch and the Financial Times report that Lilly has raised its outlook, with MarketWatch citing strong Zepbound sales and the Financial Times describing profit growth on demand for weight-loss drugs.

Headline and summary written by Mantle’s AI from the coverage below, under published rules. How this works

New to Mantle? It shows who is covering each story across the political spectrum, and highlights loaded words. How to read a storyHide the guide

The coverage spectrum counts the outlets covering a story at each of five points. A short or missing segment means that part of the spectrum is mostly quiet.

Governor Loaded verb“slams”It adds drama to what was said. The governor criticized the lawmakers; “slams” makes it sound like a fight.More neutral: criticizes lawmakers over budget delay

Highlights mark words that carry a judgement. Tap one to see why, and what a neutral writer would say. Here it is “criticizes”.

The 5-point spectrum

Far Left
Voices that strongly advocate for progressive policies and systemic change.
Left
Mainstream liberal perspectives focusing on social equality and regulation.
Center
Sources that prioritize neutral reporting and balanced viewpoints.
Right
Mainstream conservative perspectives focusing on market freedom and tradition.
Far Right
Voices that strongly advocate for conservative values and limited government.

How we measure bias

What happened

Key points

Each point shows who reports it, from Far Left to Far Right.

Eli Lilly reported third-quarter results, and MarketWatch and the Financial Times report that it raised its outlook.
One side only: the centerReported byCenter2See the outletsHide the outlets
Center
MarketWatch, Financial Times
Zepbound continues to dominate the US prescription weight-loss drug market, according to the reports.
One side only: the centerReported byCenter2See the outletsHide the outlets
Center
CNBC, MarketWatch
Analysts surveyed by LSEG expected the company's earnings and revenue to be fuelled by Zepbound and Mounjaro, according to CNBC's preview.
One outletCNBC· Center
Analysts forecast about $229 million in sales for the Foundayo obesity pill, according to StreetAccount estimates cited by CNBC.
One outletCNBC· Center
CNBC reports that Lilly faces lower net prices in the US and has agreed to buy a psychedelics drugmaker and plans to buy three vaccine makers.
One outletCNBC· Center

How each side tells it

Compare views

Every center outlet covers Eli Lilly's third-quarter earnings, though CNBC previews them while MarketWatch and the Financial Times report that the company raised its outlook. The difference is emphasis: MarketWatch leads with Zepbound sales, the FT with profit growth, and CNBC with analyst expectations and the Foundayo pill launch.

the left
No coverage yet
No left-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.
the center
3 outlets
Headlines split between a earnings preview that focuses on expectations and reports that lead with the raised outlook, Zepbound sales or profit growth.
Lilly raises outlook for third time this year as Zepbound sales soar.
MarketWatchCenterAll center headlines
the right
No coverage yet
No right-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.

The words they chose

Language to notice

Words that carry a judgement beyond the facts. Tap a highlighted word anywhere on the page to see why.

Mantle found no loaded language in this coverage. Every headline and opening was checked against Mantle’s published word list, and Mantle’s AI read all 3 articles in context. Straight reporting often has none.

See for yourself

Side by side

What each side leads with and what it leaves out. Open a side to read its headlines.

From the left

0 outlets

No left-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.

From the center

3 outlets

Leads with

raised outlook
Zepbound sales
profit growth
analyst expectations

See the 3 headlines from the centerHide the headlines

Financial TimesCenter
Eli Lilly profits surge on demand for weight-loss drugs
US drugmaker to raise its revenue outlook for the second time in three months
1 hr agoRead at Financial Times (opens in a new tab)
MarketWatchCenter
Lilly raises outlook for third time this year as Zepbound sales soar.
The drug continues to dominate the market for prescription weight-loss drugs in the U.S.
2 hr agoRead at MarketWatch (opens in a new tab)
CNBCCenter
Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
3 hr agoRead at CNBC (opens in a new tab)

From the right

0 outlets

No right-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.

The stories you read build My Mix, a private picture of which sides cover the stories you choose, kept on this device. What is My Mix?

The left is Far Left and Left together. The right is Right and Far Right together. Every outlet keeps its own five-point rating.

Who reported it when

How the coverage built up

Left
No report yet
From the outlets Mantle follows
Center
First to report
CNBC, Oct 29, 6:13 AM EDT
Right
No report yet
From the outlets Mantle follows

See the order the outlets reported inHide the order

CNBCCenterOct 29, 6:13 AM EDT
MarketWatchCenterOct 29, 7:03 AM EDT
Financial TimesCenterOct 29, 7:51 AM EDT

Times are the ones the outlets published in their own feeds, in Eastern time. Opinion is left out.

Eli Lilly reports third-quarter earnings and raises its outlook

Coverage spectrum

Key points

Compare views

the left

the center

the right

Language to notice

Side by side

From the left

From the center

Eli Lilly profits surge on demand for weight-loss drugs

Lilly raises outlook for third time this year as Zepbound sales soar.

Eli Lilly is about to report earnings. Here's what to expect

From the right

How the coverage built up

Read next

General Mills announces resealable Ziploc bags inside Cheerios boxes

DoorDash agrees to buy Instacart in a deal valued at about $17 billion

Alaska governor orders investigation of Peltola Senate campaign

Hegseth fires top Pentagon military planner Lt. Gen. Brett Sylvia

DHS disputes 60 Minutes segment on Texas father Moussa Diawara after his deportation